Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Howard L. Kaufman, M.D.

Title
Institution
Department
Address
Phone

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. UM1CA186716 (MEHNERT, JANICE) Mar 19, 2014 - Feb 29, 2020
    NIH/NCI
    Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics
    Role: Co-Principal Investigator
  2. R01CA093696 (KAUFMAN, HOWARD L.) Sep 16, 2002 - Aug 31, 2005
    NIH
    ENHANCING TUMOR VACCINES WITH CO-STIMULATORY MOLECULES
    Role: Principal Investigator
  3. K08CA079881 (KAUFMAN, HOWARD L.) Aug 1, 2000 - Jul 31, 2004
    NIH
    ANTIGEN PRESENTATION BY CEA DIRECTED TUMOR VACCINES
    Role: Principal Investigator
  4. R03CA080647 (KAUFMAN, HOWARD L.) Sep 30, 1998 - Sep 29, 2001
    NIH
    CANARYPOX VACCINE EXPRESSIONG CEA AND B7
    Role: Principal Investigator
  5. R41HD034012 (KAUFMAN, HOWARD L.) Aug 18, 1995 - Aug 15, 1996
    NIH
    PHASE MODULATED IR SPECTROSCOPY TO MEASURE CEREBRAL HB02
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2021 Oct 12; 12(21):2231. PMID: 34676056.
    Citations:    Fields:    
  2. Saqlain F, Shalhout SZ, Emerick KS, Kaufman HL, Chen YE, Cusack JC, Wright K, Miller DM. Diagnostic yield of staging brain magnetic resonance imaging is low in Merkel cell carcinoma: A single-institution cohort study. J Am Acad Dermatol. 2021 Sep 06. PMID: 34499987.
    Citations:    Fields:    
  3. Andtbacka RHI, Curti B, Daniels GA, Hallmeyer S, Whitman ED, Lutzky J, Spitler LE, Zhou K, Bommareddy PK, Grose M, Wang M, Wu C, Kaufman HL. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. J Clin Oncol. 2021 Aug 31; JCO2003246. PMID: 34464163.
    Citations:    Fields:    
  4. Shalhout SZ, Emerick KS, Kaufman HL, Miller DM. Immunotherapy for Non-melanoma Skin Cancer. Curr Oncol Rep. 2021 08 27; 23(11):125. PMID: 34448958.
    Citations:    Fields:    
  5. Shalhout SZ, Kaufman HL, Sullivan RJ, Lawrence D, Miller DM. Immune Checkpoint Inhibition in Marjolin Ulcer: A Case Series. J Immunother. 2021 Jul-Aug 01; 44(6):234-238. PMID: 34100836.
    Citations:    Fields:    
  6. Kaufman HL. Can Biomarkers Guide Oncolytic Virus Immunotherapy? Clin Cancer Res. 2021 Jun 15; 27(12):3278-3279. PMID: 33849964.
    Citations:    Fields:    
  7. Kaufman HL, Maciorowski D. Advancing oncolytic virus therapy by understanding the biology. Nat Rev Clin Oncol. 2021 04; 18(4):197-198. PMID: 33686265.
    Citations: 1     Fields:    Translation:HumansCells
  8. Clark JI, Curti B, Davis EJ, Kaufman H, Amin A, Alva A, Logan TF, Hauke R, Miletello GP, Vaishampayan U, Johnson DB, White RL, Wiernik PH, Dutcher JP. Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2. J Investig Med. 2021 Feb 04. PMID: 33542072.
    Citations:    Fields:    
  9. Kaufman HL. Can Surgeons Expand the Role of Oncolytic Viruses for Cancer Treatment? An Editorial Comment on "Fighting Fire with Fire: Oncolytic Virotherapy in Thoracic Malignancies". Ann Surg Oncol. 2021 May; 28(5):2432-2433. PMID: 33475883.
    Citations:    Fields:    Translation:HumansCells
  10. Shalhout SZ, Park JC, Emerick KS, Sullivan RJ, Kaufman HL, Miller DM. Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2021 Oct; 85(4):1038-1040. PMID: 33476726.
    Citations: 2     Fields:    
  11. Seethapathy H, Lee MD, Strohbehn IA, Efe O, Rusibamayila N, Chute DF, Colvin RB, Rosales IA, Fadden RM, Reynolds KL, Sullivan RJ, Kaufman HL, Jhaveri KD, Sise ME. Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrol Dial Transplant. 2020 Dec 23. PMID: 33355659.
    Citations:    Fields:    
  12. Larocca CA, LeBoeuf NR, Silk AW, Kaufman HL. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions. Am J Clin Dermatol. 2020 Dec; 21(6):821-832. PMID: 32767272.
    Citations: 4     Fields:    Translation:HumansCells
  13. Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 2020 11; 8(2). PMID: 33199512.
    Citations: 4     Fields:    Translation:Humans
  14. Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer. 2020 10; 8(2). PMID: 33046622.
    Citations: 20     Fields:    Translation:HumansCells
  15. Kim J, Zhang J, Cha Y, Kolitz S, Funt J, Escalante Chong R, Barrett S, Kusko R, Zeskind B, Kaufman H. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19). J Transl Med. 2020 06 25; 18(1):257. PMID: 32586380.
    Citations: 26     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  16. Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1). PMID: 32300051.
    Citations: 33     Fields:    Translation:HumansCellsPHPublic Health
  17. Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020 03; 8(1). PMID: 32209603.
    Citations: 117     Fields:    Translation:Humans
  18. Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Front Oncol. 2019; 9:1483. PMID: 31998643.
    Citations: 3     
  19. Pai S, Blaisdell D, Brodie R, Carlson R, Finnes H, Galioto M, Jensen RE, Valuck T, Sepulveda AR, Kaufman HL. Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. J Immunother Cancer. 2020 01; 8(1). PMID: 31949040.
    Citations: 1     Fields:    Translation:Humans
  20. Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, Estupinian R, Aboelatta MM, Buddhadev S, Tarabichi S, Lee M, Li S, Medina DJ, Giurini EF, Gupta KH, Guevara-Aleman G, Rossi M, Nowicki C, Abed A, Goldufsky JW, Broucek JR, Redondo RE, Rotter D, Jhawar SR, Wang SJ, Kohlhapp FJ, Kaufman HL, Thomas PG, Gupta V, Kuzel TM, Reiser J, Paras J, Kane MP, Singer EA, Malhotra J, Denzin LK, Sant'Angelo DB, Rabson AB, Lee LY, Lasfar A, Langenfeld J, Schenkel JM, Fidler MJ, Ruiz ES, Marzo AL, Rudra JS, Silk AW, Zloza A. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci U S A. 2020 01 14; 117(2):1119-1128. PMID: 31888983.
    Citations: 28     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  21. Bommareddy PK, Peters C, Kaufman HL. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption. Methods Enzymol. 2020; 635:167-184. PMID: 32122544.
    Citations: 1     Fields:    Translation:HumansCells
  22. Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, Coffin RS. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer. 2019 08 10; 7(1):214. PMID: 31399043.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  23. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 Jul 04; 7(1):167. PMID: 31272507.
    Citations: 1     Fields:    
  24. Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, ?hrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019 06 06; 7(1):145. PMID: 31171039.
    Citations: 52     Fields:    Translation:HumansCellsCTClinical Trials
  25. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131. PMID: 31113486.
    Citations: 27     Fields:    Translation:HumansAnimals
  26. Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 05 17; 7(1):129. PMID: 31101066.
    Citations: 20     Fields:    Translation:Humans
  27. Bommareddy PK, Zloza A, Rabkin SD, Kaufman HL. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology. 2019; 8(7):1591875. PMID: 31143509.
    Citations: 23     
  28. Hennessy ML, Bommareddy PK, Boland G, Kaufman HL. Oncolytic Immunotherapy. Surg Oncol Clin N Am. 2019 07; 28(3):419-430. PMID: 31079797.
    Citations:    Fields:    Translation:HumansAnimalsCells
  29. Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D. Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. J Biol Methods. 2019; 6(2). PMID: 31123687.
    Citations: 2     
  30. Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. J Immunother Cancer. 2019 03 27; 7(1):84. PMID: 30917871.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  31. Bommareddy PK, Rabkin SD, Kaufman HL. Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. Oncoimmunology. 2019; 8(4):e1571390. PMID: 30906668.
    Citations:    
  32. Ugolini H, Bryan J, Hennessy M, Kaufman HL, D'Angelo S. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma. Clin J Oncol Nurs. 2019 02 01; 23(1):E1-E9. PMID: 30682006.
    Citations: 2     Fields:    Translation:Humans
  33. Kaufman HL, Bommareddy PK. Two roads for oncolytic immunotherapy development. J Immunother Cancer. 2019 02 01; 7(1):26. PMID: 30709365.
    Citations: 12     Fields:    Translation:HumansCells
  34. Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med. 2018 12 12; 10(471). PMID: 30541787.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  35. D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol. 2018 09 01; 4(9):e180077. PMID: 29566106.
    Citations: 98     Fields:    Translation:HumansCTClinical Trials
  36. Kaufman HL, Schwartz LH, William WN, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2018 Nov; 144(11):2245-2261. PMID: 30132118.
    Citations: 9     Fields:    Translation:Humans
  37. Kaufman HL, Dias Barbosa C, Guillemin I, Lambert J, Mahnke L, Bharmal M. Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences. Patient. 2018 08; 11(4):439-449. PMID: 29512061.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  38. Bommareddy PK, Shettigar M, Kaufman HL. Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018 Aug; 18(8):536. PMID: 29930315.
    Citations:    Fields:    
  39. Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018 08; 18(8):498-513. PMID: 29743717.
    Citations: 127     Fields:    Translation:HumansCells
  40. Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018 07 11; 6(1):69. PMID: 29996914.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  41. Marciscano AE, Gulley JL, Kaufman HL. Avelumab: is it time to get excited? Expert Rev Anticancer Ther. 2018 09; 18(9):815-821. PMID: 29939083.
    Citations: 1     Fields:    Translation:Humans
  42. Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J. Immune oncology, immune responsiveness and the theory of everything. J Immunother Cancer. 2018 06 05; 6(1):50. PMID: 29871670.
    Citations: 22     Fields:    Translation:Humans
  43. Kaufman HL, Margolin K, Sullivan R. Management of Metastatic Melanoma in 2018. JAMA Oncol. 2018 06 01; 4(6):857-858. PMID: 29621376.
    Citations: 11     Fields:    Translation:Humans
  44. Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44. PMID: 29848375.
    Citations: 17     Fields:    Translation:Humans
  45. Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest. 2018 06 01; 128(6):2325-2338. PMID: 29533922.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  46. Chan IS, Bhatia S, Kaufman HL, Lipson EJ. Immunotherapy for Merkel cell carcinoma: a turning point in patient care. J Immunother Cancer. 2018 03 23; 6(1):23. PMID: 29566749.
    Citations: 13     Fields:    Translation:Humans
  47. Bommareddy PK, Kaufman HL. Unleashing the therapeutic potential of oncolytic viruses. J Clin Invest. 2018 04 02; 128(4):1258-1260. PMID: 29504947.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  48. Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. J Natl Cancer Inst. 2018 03 01; 110(3):316-320. PMID: 29155997.
    Citations: 51     Fields:    Translation:HumansCells
  49. Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM. Quantitative Analysis of Immune Infiltrates in Primary Melanoma. Cancer Immunol Res. 2018 04; 6(4):481-493. PMID: 29467127.
    Citations: 34     Fields:    Translation:HumansCells
  50. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after =1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018 01 19; 6(1):7. PMID: 29347993.
    Citations: 85     Fields:    Translation:HumansCTClinical Trials
  51. Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017 12 19; 5(1):102. PMID: 29254506.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  52. Kaufman HL, Hunger M, Hennessy M, Schlichting M, Bharmal M. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncol. 2018 Feb; 14(3):255-266. PMID: 29219612.
    Citations: 5     Fields:    Translation:Humans
  53. Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precis Oncol. 2017; 2017. PMID: 29951597.
    Citations: 16     
  54. Hughes T, Broucek J, Iodice G, Bommareddy PK, Basu S, Kaufman HL. Metastasectomy following incomplete response to high-dose interleukin-2. J Surg Oncol. 2018 Mar; 117(4):572-578. PMID: 29165819.
    Citations:    Fields:    Translation:Humans
  55. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017 11 21; 5(1):95. PMID: 29162153.
    Citations: 406     Fields:    Translation:Humans
  56. Cohen-Solal KA, Kaufman HL, Lasfar A. Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development. Pigment Cell Melanoma Res. 2018 03; 31(2):241-252. PMID: 29090514.
    Citations: 7     Fields:    Translation:HumansCells
  57. Everett AS, Pavlidakey PG, Contreras CM, De Los Santos JF, Kim JY, McKee SB, Kaufman HL, Conry RM. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. J Cutan Pathol. 2018 Jan; 45(1):48-53. PMID: 28940544.
    Citations: 5     Fields:    Translation:Humans
  58. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 06 10; 36(17):1658-1667. PMID: 28981385.
    Citations: 175     Fields:    Translation:HumansCellsCTClinical Trials
  59. Bommareddy PK, Kaufman HL. Avelumab and other recent advances in Merkel cell carcinoma. Future Oncol. 2017 Dec; 13(30):2771-2783. PMID: 28976209.
    Citations: 2     Fields:    Translation:HumansCells
  60. Kaufman HL. Finding gold in tumour immunotherapy. Lancet Oncol. 2017 10; 18(10):e561. PMID: 28971820.
    Citations:    Fields:    Translation:Humans
  61. Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf. 2017 Dec; 16(12):1347-1357. PMID: 28929820.
    Citations: 13     Fields:    Translation:Humans
  62. Kaufman HL, Andtbacka RHI, Collichio FA, Wolf M, Zhao Z, Shilkrut M, Puzanov I, Ross M. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. J Immunother Cancer. 2017 09 19; 5(1):72. PMID: 28923101.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  63. Schadendorf D, Nghiem P, Bhatia S, Hauschild A, Saiag P, Mahnke L, Hariharan S, Kaufman HL. Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. Oncoimmunology. 2017; 6(10):e1338237. PMID: 29123950.
    Citations: 11     
  64. Kaufman HL. Rational Combination Immunotherapy: Understand the Biology. Cancer Immunol Res. 2017 05; 5(5):355-356. PMID: 28465453.
    Citations: 3     Fields:    Translation:HumansAnimals
  65. Patel A, Kaufman HL, Disis ML. Next generation approaches for tumor vaccination. Chin Clin Oncol. 2017 Apr; 6(2):19. PMID: 28482672.
    Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
  66. Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017 Jun; 13(14):1263-1279. PMID: 28350180.
    Citations: 33     Fields:    Translation:Humans
  67. Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM. First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017 Aug 01; 23(15):4163-4169. PMID: 28331050.
    Citations: 51     Fields:    Translation:HumansCTClinical Trials
  68. Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16. PMID: 28239469.
    Citations: 114     Fields:    Translation:HumansAnimals
  69. Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am J Clin Dermatol. 2017 Feb; 18(1):1-15. PMID: 27988837.
    Citations: 55     Fields:    Translation:HumansAnimalsCells
  70. Bommareddy PK, Silk AW, Kaufman HL. Intratumoral Approaches for the Treatment of Melanoma. Cancer J. 2017 Jan/Feb; 23(1):40-47. PMID: 28114253.
    Citations: 15     Fields:    Translation:HumansAnimals
  71. Harrington KJ, Andtbacka RH, Collichio F, Downey G, Chen L, Szabo Z, Kaufman HL. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 2016; 9:7081-7093. PMID: 27895500.
    Citations: 28     
  72. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 08; 7(45):74380-74392. PMID: 27602582.
    Citations: 54     Fields:    Translation:HumansAnimalsCells
  73. Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer. 2017 02; 15(1):31-41.e4. PMID: 27916626.
    Citations: 7     Fields:    Translation:Humans
  74. Zloza A, Dharmadhikari ND, Huelsmann EJ, Broucek JR, Hughes T, Kohlhapp FJ, Kaufman HL. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. Cancer Immunol Immunother. 2017 01; 66(1):9-16. PMID: 27757560.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  75. Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, Sowell RT, Kühner R, Burd S, Kubasiak JC, Nabatiyan A, Marshall S, Bommareddy PK, Li S, Newman JH, Monken CE, Shafikhani SH, Marzo AL, Guevara-Patino JA, Lasfar A, Thomas PG, Lattime EC, Kaufman HL, Zloza A. Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. Cell Rep. 2016 10 18; 17(4):957-965. PMID: 27760326.
    Citations: 8     Fields:    Translation:AnimalsCells
  76. Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544. PMID: 27714434.
    Citations: 23     Fields:    Translation:Humans
  77. Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016; 4:52. PMID: 27660706.
    Citations: 10     Fields:    
  78. Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016; 4:53. PMID: 27660707.
    Citations: 98     Fields:    
  79. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct; 17(10):1374-1385. PMID: 27592805.
    Citations: 357     Fields:    Translation:HumansCTClinical Trials
  80. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2016 08 30; 15(9):660. PMID: 30907381.
    Citations: 16     Fields:    
  81. Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist. 2016 Nov; 21(11):1315-1325. PMID: 27566247.
    Citations: 24     Fields:    
  82. Jhawar SR, Kaufman HL, Goyal S. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016 Nov 15; 122(22):3576-3577. PMID: 27495907.
    Citations:    Fields:    
  83. Emens LA, Butterfield LH, Hodi FS, Marincola FM, Kaufman HL. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016; 4:42. PMID: 27437105.
    Citations: 14     Fields:    
  84. Andtbacka RH, Agarwala SS, Ollila DW, Hallmeyer S, Milhem M, Amatruda T, Nemunaitis JJ, Harrington KJ, Chen L, Shilkrut M, Ross M, Kaufman HL. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head Neck. 2016 12; 38(12):1752-1758. PMID: 27407058.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  85. Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM. IFN-? cancer immunotherapy: new kid on the block. Immunotherapy. 2016 07; 8(8):877-88. PMID: 27381684.
    Citations: 9     Fields:    Translation:HumansAnimals
  86. Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, Chen L, Shilkrut M, Kaufman HL. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Ann Surg Oncol. 2016 12; 23(13):4169-4177. PMID: 27342831.
    Citations: 83     Fields:    Translation:HumansCellsCTClinical Trials
  87. Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM. Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. J Immunother Cancer. 2016; 4:37. PMID: 27330810.
    Citations:    Fields:    
  88. Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, Kaufman HL, Andtbacka RH. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016 08 01; 34(22):2619-26. PMID: 27298410.
    Citations: 178     Fields:    Translation:HumansCellsCTClinical Trials
  89. Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, Bhanot G, White EP, DiPaola RS, Lovell A, Cheng J, Ganesan S. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016 06 01; 126(6):2334-40. PMID: 27159395.
    Citations: 114     Fields:    Translation:Humans
  90. Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016; 4:12. PMID: 26981242.
    Citations: 31     Fields:    
  91. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb; 2(2):234-40. PMID: 26633184.
    Citations: 168     Fields:    Translation:Humans
  92. Koshenkov VP, Broucek J, Kaufman HL. Surgical Management of Melanoma. Cancer Treat Res. 2016; 167:149-79. PMID: 26601862.
    Citations: 5     Fields:    Translation:Humans
  93. Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for Immunotherapy: Current Developments and Challenges. Am Soc Clin Oncol Educ Book. 2016; 35:e493-503. PMID: 27249758.
    Citations: 36     Fields:    Translation:HumansCells
  94. Kohlhapp FJ, Kaufman HL. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clin Cancer Res. 2016 Mar 01; 22(5):1048-54. PMID: 26719429.
    Citations: 82     Fields:    Translation:HumansCells
  95. Hughes T, Klairmont M, Sharfman WH, Kaufman HL. Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma. . 2015 Sep 29; 0. PMID: 26418961.
    Citations: 7     
  96. Stein MN, Hussain M, Stadler WM, Liu G, Tereshchenko IV, Goodin S, Jeyamohan C, Kaufman HL, Mehnert J, DiPaola RS. A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer. 2016 Feb; 14(1):22-7. PMID: 26476589.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  97. Kohlhapp FJ, Zloza A, Kaufman HL. Talimogene laherparepvec (T-VEC) as cancer immunotherapy. Drugs Today (Barc). 2015 Sep; 51(9):549-58. PMID: 26488034.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  98. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015 09; 14(9):642-62. PMID: 26323545.
    Citations: 328     Fields:    Translation:HumansAnimalsCells
  99. Goyal S, Silk AW, Tian S, Mehnert J, Danish S, Ranjan S, Kaufman HL. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol. 2015 Aug; 1(5):668-76. PMID: 26181286.
    Citations: 24     Fields:    Translation:Humans
  100. Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol. 2015 Jun 25; 16:133. PMID: 26109056.
    Citations: 121     Fields:    Translation:HumansCells
  101. Kaufman HL. Combination Immunotherapy for Melanoma. JAMA Oncol. 2015 Jun; 1(3):387-8. PMID: 26181189.
    Citations: 2     Fields:    Translation:Humans
  102. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 01; 33(25):2780-8. PMID: 26014293.
    Citations: 740     Fields:    Translation:HumansCellsCTClinical Trials
  103. Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, Schenkel JM, Masopust D, Zloza A, Kaufman HL. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer. 2015; 3:18. PMID: 25992289.
    Citations: 25     Fields:    
  104. Dharmadhikari N, Mehnert JM, Kaufman HL. Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol. 2015 Mar; 16(3):326. PMID: 25777572.
    Citations: 18     Fields:    Translation:HumansCells
  105. de Vries CR, Kaufman HL, Lattime EC. Oncolytic viruses: focusing on the tumor microenvironment. Cancer Gene Ther. 2015 Mar; 22(4):169-71. PMID: 25721204.
    Citations: 10     Fields:    Translation:HumansCells
  106. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology. 2015 Apr; 4(4):e998538. PMID: 26137416.
    Citations: 57     
  107. Goldufsky J, Wood S, Hajihossainlou B, Rehman T, Majdobeh O, Kaufman HL, Ruby CE, Shafikhani SH. Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J Med Microbiol. 2015 Feb; 64(Pt 2):164-73. PMID: 25627204.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  108. Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother. 2015 Apr; 64(4):459-65. PMID: 25603775.
    Citations: 6     Fields:    Translation:Humans
  109. Kaufman HL. Precision immunology: the promise of immunotherapy for the treatment of cancer. J Clin Oncol. 2015 Apr 20; 33(12):1315-7. PMID: 25605852.
    Citations: 1     Fields:    Translation:HumansCells
  110. Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, Kaufman HL. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015; 15(12):1389-403. PMID: 26558498.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  111. Doscas ME, Williamson AJ, Usha L, Bogachkov Y, Rao GS, Xiao F, Wang Y, Ruby C, Kaufman H, Zhou J, Williams JW, Li Y, Xu X. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014 Oct; 16(10):824-34. PMID: 25379019.
    Citations: 15     Fields:    Translation:HumansCells
  112. Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins MB. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J Immunother Cancer. 2014 Sep 16; 2(1):26. PMID: 31546315.
    Citations: 19